Lv1
20 积分 2024-06-30 加入
An FDA oncology analysis of CD3 bispecific constructs and first-in-human dose selection
19天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
24天前
已完结
IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
25天前
已完结
Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab
1个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
2个月前
已完结
First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
6个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
6个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
6个月前
已完结
皖公网安备34019202002308
